The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Changes in PD-L1 and tumor mutational burden between paired samples and relationship to immune checkpoint inhibitor outcomes in non-small cell lung cancer.
 
Alessandro Di Federico
No Relationships to Disclose
 
Stephanie Leigh Alden
No Relationships to Disclose
 
James William Smithy
No Relationships to Disclose
 
Biagio Ricciuti
Consulting or Advisory Role - Regeneron
 
Joao Victor Machado Alessi
No Relationships to Disclose
 
Xinan Wang
No Relationships to Disclose
 
Giuseppe Lamberti
No Relationships to Disclose
 
Federica Pecci
No Relationships to Disclose
 
Malini Marion Gandhi
No Relationships to Disclose
 
Liam Flinn Spurr
Employment - Genzyme (I)
Stock and Other Ownership Interests - Applied Genetic Technologies Corporation; CRISPR Therapeutics; Novavax; Vertex
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; Archer; ARIAD; AstraZeneca; AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; EMD Serono; Foundation Medicine; Genentech; Gilead Sciences; Gritstone Bio; Hengrui Therapeutics; Instil Bio; Janssen Oncology; Maverick Therapeutics; Merck; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Panasonic; Pfizer; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst)